title: Editorial.
authors.affiliation: Takeda Pharmaceuticals International Company Cambridge, MA USA. Suresh.Balani@takeda.com.
authors.forename: Suresh K
authors.initials: SK
authors.lastname: Balani
mesh_terms: D000818:Animals; D043303:Aryldialkylphosphatase / Q000037:antagonists & inhibitors / Q000097:blood; D001528:Behcet Syndrome / Q000097:blood / Q000188:drug therapy / Q000201:enzymology; D001711:Biotransformation; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007527:Isoenzymes; D008099:Liver / Q000201:enzymology; D013379:Substrate Specificity
chemical_list: D004791:Enzyme Inhibitors; D007527:Isoenzymes; D003577:Cytochrome P-450 Enzyme System; D043303:Aryldialkylphosphatase; C468406:PON1 protein, human